Chemiluminescence Immunoassay Market Size, Share, Trends, Growth Outlook

Chemiluminescence Immunoassay Market is estimated to increase at a Compounded Annual Growth Rate of 8.7% CAGR over the forecast period from 2024 to 2030

The Chemiluminescence Immunoassay Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Consumables, Instruments), By Technology (Chemiluminescence Enzyme Technology (CLEIA), Electrochemiluminescence immunoassay (ECLI), Microparticle Chemiluminescence Immunoassay), By Sample (Blood, Urine, Saliva, Others), By Application (Infectious Disease, Endocrinology, Oncology, Cardiology, Others), By End-User (Hospitals, Clinical Laboratories, Pharmaceuticals Companies, Contract Research Organizations, Others).

An Introduction to Chemiluminescence Immunoassay Market in 2024

Chemiluminescence immunoassay (CLIA) is a laboratory technique used to detect and quantify specific proteins or biomolecules in biological samples by measuring the light emitted during a chemical reaction between an enzyme-labeled antibody and a substrate molecule. In 2024, CLIA continues to be a widely used immunoassay method in clinical diagnostics, research laboratories, and pharmaceutical development due to its high sensitivity, wide dynamic range, and versatility. CLIA assays are employed for the detection of various analytes, including hormones, tumor markers, infectious agents, and therapeutic drugs, in diverse sample matrices such as serum, plasma, urine, and tissue lysates. Moreover, with the development of automated CLIA platforms, multiplexed assays, and assay kits, CLIA enables high-throughput testing, rapid turnaround times, and standardized results across laboratory settings. By providing accurate and reliable measurements of biomarkers, CLIA plays a crucial role in disease diagnosis, prognosis, and monitoring, facilitating clinical decision-making and patient management in a wide range of medical specialties, including endocrinology, oncology, infectious diseases, and autoimmune disorders.

Market Trend: Increasing Adoption in Clinical Diagnostics

A significant trend in the chemiluminescence immunoassay (CLIA) market is the rising adoption of CLIA technology in clinical diagnostics. CLIA offers several advantages over traditional immunoassay methods, including high sensitivity, wide dynamic range, and rapid assay turnaround times, making it well-suited for the detection of low-abundance analytes and biomarkers in clinical samples. As healthcare providers strive to improve diagnostic accuracy, enhance patient care, and streamline laboratory workflows, there is a growing preference for CLIA platforms for a wide range of applications, including infectious disease testing, hormone assays, cancer biomarker detection, and therapeutic drug monitoring. The increasing adoption of CLIA technology in clinical laboratories and point-of-care settings is driving market growth and fueling innovation in assay development and automation solutions to meet the evolving needs of healthcare professionals and patients.

Market Driver: Demand for High-Throughput and Multiplex Assay Solutions

The primary driver fueling the growth of the chemiluminescence immunoassay market is the growing demand for high-throughput and multiplex assay solutions for clinical diagnostics and research applications. CLIA platforms offer the ability to simultaneously measure multiple analytes in a single sample, providing comprehensive insights into disease states, treatment responses, and patient outcomes. With the increasing complexity of disease profiles and the need for personalized treatment approaches, there is a growing demand for multiplex CLIA assays that enable the simultaneous detection of multiple biomarkers associated with a particular disease or therapeutic pathway. Additionally, the scalability and high-throughput capabilities of CLIA platforms make them ideal for large-scale screening programs, epidemiological studies, and population health monitoring initiatives. As healthcare systems worldwide seek to improve disease detection, surveillance, and management, the demand for high-throughput and multiplex CLIA solutions is expected to drive market growth and foster innovation in assay development and automation technologies.

Market Opportunity: Expansion into Point-of-Care Testing and Near-Patient Settings

A potential opportunity for the chemiluminescence immunoassay market lies in the expansion into point-of-care testing (POCT) and near-patient settings to enable rapid and decentralized diagnostic testing. While CLIA technology has traditionally been employed in centralized laboratory settings, there is a growing need for rapid diagnostic solutions that can deliver actionable results at the point of care or near-patient settings, such as clinics, emergency departments, and physician offices. By miniaturizing CLIA platforms, simplifying assay procedures, and integrating them with portable instrumentation, manufacturers can develop POCT solutions that offer the sensitivity and specificity of laboratory-based CLIA assays while enabling rapid turnaround times and on-demand testing. The adoption of CLIA-based POCT solutions has the potential to improve patient outcomes by facilitating timely diagnosis, treatment initiation, and monitoring of disease progression, particularly in resource-limited settings or during public health emergencies. By leveraging CLIA technology for POCT applications, manufacturers can address unmet clinical needs, expand market reach, and capitalize on opportunities to transform diagnostic testing paradigms and improve healthcare delivery worldwide.

Chemiluminescence Immunoassay Market Share Analysis: Electrochemiluminescence Immunoassay (ECLI) is the fastest growing segment over the forecast period to 2030

The segment of Electrochemiluminescence Immunoassay (ECLI) emerges as the fastest-growing segment in the chemiluminescence immunoassay market, propelled by several key factors contributing to its widespread adoption and demand. ECLI technology offers enhanced sensitivity, specificity, and dynamic range compared to traditional chemiluminescence enzyme technology (CLEIA) and other immunoassay platforms. ECLI leverages electrochemical reactions to generate luminescent signals, enabling precise quantification of analytes in biological samples with minimal background noise. This high-performance assay technology is particularly well-suited for a wide range of applications, including infectious disease testing, endocrinology, oncology, and cardiology, where accurate and reliable measurement of biomarkers is critical for disease diagnosis, prognosis, and treatment monitoring. Moreover, the versatility of ECLI technology allows for multiplexing and automation, streamlining laboratory workflows and enhancing efficiency for hospitals, clinical laboratories, pharmaceutical companies, contract research organizations, and other end-users. As healthcare providers and researchers increasingly prioritize rapid, sensitive, and multiplexed immunoassay platforms for diagnostic and research purposes, the demand for ECLI-based assays is expected to continue driving substantial growth in this segment of the chemiluminescence immunoassay market.

Chemiluminescence Immunoassay Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories, Danaher Corp, DiaSorin S.p.A., Diatron, EUROIMMUN Medizinische Labordiagnostika AG, F. Hoffmann-La Roche Ltd, Getein Biotech Inc, Quidel Corp, Shenzhen Mindray Bio-Medical Electronics Co. Ltd, Siemens Healthineers AG, Sysmex Corp, Werfen

Chemiluminescence Immunoassay Market Segmentation

By Product
Consumables
Instruments
By Technology
Chemiluminescence Enzyme Technology (CLEIA)
Electrochemiluminescence immunoassay (ECLI)
Microparticle Chemiluminescence Immunoassay
By Sample
Blood
Urine
Saliva
Others
By Application
Infectious Disease
Endocrinology
Oncology
Cardiology
Others
By End-User
Hospitals
Clinical Laboratories
Pharmaceuticals Companies
Contract Research Organizations
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Chemiluminescence Immunoassay Market Companies

Abbott Laboratories
Danaher Corp
DiaSorin S.p.A.
Diatron
EUROIMMUN Medizinische Labordiagnostika AG
F. Hoffmann-La Roche Ltd
Getein Biotech Inc
Quidel Corp
Shenzhen Mindray Bio-Medical Electronics Co. Ltd
Siemens Healthineers AG
Sysmex Corp
Werfen

Reasons to Buy the Chemiluminescence Immunoassay Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Chemiluminescence Immunoassay Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Chemiluminescence Immunoassay Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Chemiluminescence Immunoassay Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Chemiluminescence Immunoassay Market Size Outlook, $ Million, 2021 to 2030
3.2 Chemiluminescence Immunoassay Market Outlook by Type, $ Million, 2021 to 2030
3.3 Chemiluminescence Immunoassay Market Outlook by Product, $ Million, 2021 to 2030
3.4 Chemiluminescence Immunoassay Market Outlook by Application, $ Million, 2021 to 2030
3.5 Chemiluminescence Immunoassay Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Chemiluminescence Immunoassay Industry
4.2 Key Market Trends in Chemiluminescence Immunoassay Industry
4.3 Potential Opportunities in Chemiluminescence Immunoassay Industry
4.4 Key Challenges in Chemiluminescence Immunoassay Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Chemiluminescence Immunoassay Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Chemiluminescence Immunoassay Market Outlook by Segments
7.1 Chemiluminescence Immunoassay Market Outlook by Segments, $ Million, 2021- 2030
By Product
Consumables
Instruments
By Technology
Chemiluminescence Enzyme Technology (CLEIA)
Electrochemiluminescence immunoassay (ECLI)
Microparticle Chemiluminescence Immunoassay
By Sample
Blood
Urine
Saliva
Others
By Application
Infectious Disease
Endocrinology
Oncology
Cardiology
Others
By End-User
Hospitals
Clinical Laboratories
Pharmaceuticals Companies
Contract Research Organizations
Others

8 North America Chemiluminescence Immunoassay Market Analysis and Outlook To 2030
8.1 Introduction to North America Chemiluminescence Immunoassay Markets in 2024
8.2 North America Chemiluminescence Immunoassay Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Chemiluminescence Immunoassay Market size Outlook by Segments, 2021-2030
By Product
Consumables
Instruments
By Technology
Chemiluminescence Enzyme Technology (CLEIA)
Electrochemiluminescence immunoassay (ECLI)
Microparticle Chemiluminescence Immunoassay
By Sample
Blood
Urine
Saliva
Others
By Application
Infectious Disease
Endocrinology
Oncology
Cardiology
Others
By End-User
Hospitals
Clinical Laboratories
Pharmaceuticals Companies
Contract Research Organizations
Others

9 Europe Chemiluminescence Immunoassay Market Analysis and Outlook To 2030
9.1 Introduction to Europe Chemiluminescence Immunoassay Markets in 2024
9.2 Europe Chemiluminescence Immunoassay Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Chemiluminescence Immunoassay Market Size Outlook by Segments, 2021-2030
By Product
Consumables
Instruments
By Technology
Chemiluminescence Enzyme Technology (CLEIA)
Electrochemiluminescence immunoassay (ECLI)
Microparticle Chemiluminescence Immunoassay
By Sample
Blood
Urine
Saliva
Others
By Application
Infectious Disease
Endocrinology
Oncology
Cardiology
Others
By End-User
Hospitals
Clinical Laboratories
Pharmaceuticals Companies
Contract Research Organizations
Others

10 Asia Pacific Chemiluminescence Immunoassay Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Chemiluminescence Immunoassay Markets in 2024
10.2 Asia Pacific Chemiluminescence Immunoassay Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Chemiluminescence Immunoassay Market size Outlook by Segments, 2021-2030
By Product
Consumables
Instruments
By Technology
Chemiluminescence Enzyme Technology (CLEIA)
Electrochemiluminescence immunoassay (ECLI)
Microparticle Chemiluminescence Immunoassay
By Sample
Blood
Urine
Saliva
Others
By Application
Infectious Disease
Endocrinology
Oncology
Cardiology
Others
By End-User
Hospitals
Clinical Laboratories
Pharmaceuticals Companies
Contract Research Organizations
Others

11 South America Chemiluminescence Immunoassay Market Analysis and Outlook To 2030
11.1 Introduction to South America Chemiluminescence Immunoassay Markets in 2024
11.2 South America Chemiluminescence Immunoassay Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Chemiluminescence Immunoassay Market size Outlook by Segments, 2021-2030
By Product
Consumables
Instruments
By Technology
Chemiluminescence Enzyme Technology (CLEIA)
Electrochemiluminescence immunoassay (ECLI)
Microparticle Chemiluminescence Immunoassay
By Sample
Blood
Urine
Saliva
Others
By Application
Infectious Disease
Endocrinology
Oncology
Cardiology
Others
By End-User
Hospitals
Clinical Laboratories
Pharmaceuticals Companies
Contract Research Organizations
Others
12 Middle East and Africa Chemiluminescence Immunoassay Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Chemiluminescence Immunoassay Markets in 2024
12.2 Middle East and Africa Chemiluminescence Immunoassay Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Chemiluminescence Immunoassay Market size Outlook by Segments, 2021-2030
By Product
Consumables
Instruments
By Technology
Chemiluminescence Enzyme Technology (CLEIA)
Electrochemiluminescence immunoassay (ECLI)
Microparticle Chemiluminescence Immunoassay
By Sample
Blood
Urine
Saliva
Others
By Application
Infectious Disease
Endocrinology
Oncology
Cardiology
Others
By End-User
Hospitals
Clinical Laboratories
Pharmaceuticals Companies
Contract Research Organizations
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Danaher Corp
DiaSorin S.p.A.
Diatron
EUROIMMUN Medizinische Labordiagnostika AG
F. Hoffmann-La Roche Ltd
Getein Biotech Inc
Quidel Corp
Shenzhen Mindray Bio-Medical Electronics Co. Ltd
Siemens Healthineers AG
Sysmex Corp
Werfen

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Consumables
Instruments
By Technology
Chemiluminescence Enzyme Technology (CLEIA)
Electrochemiluminescence immunoassay (ECLI)
Microparticle Chemiluminescence Immunoassay
By Sample
Blood
Urine
Saliva
Others
By Application
Infectious Disease
Endocrinology
Oncology
Cardiology
Others
By End-User
Hospitals
Clinical Laboratories
Pharmaceuticals Companies
Contract Research Organizations
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)